Saltar al contenido
Merck

Piroxicam induced pulmonary infiltrates and eosinophilia.

The Journal of rheumatology (1994-08-01)
P Pfitzenmeyer, M Meier, P Zuck, G Peiffer, P Masson, A Turcu, F Piard, P Camus
RESUMEN

We describe 2 patients who developed pulmonary infiltrates while being treated with piroxicam. There was no satisfactory explanation other than drug induced lung disease for their illness. They had no exposure to pneumotoxic drugs or aerocontaminants. Microorganisms were not cultured in sputum or bronchoaveolar lavage. There was no underlying illness with possible lung involvement. Pulmonary infiltrates developed during piroxicam therapy, disappeared after drug withdrawal and recurred following rechallenge.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Piroxicam, ≥98% (TLC)
USP
Piroxicam, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Piroxicam, meets USP testing specifications
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard
Piroxicam, European Pharmacopoeia (EP) Reference Standard